Thrombosis
From the Journals
AVERT: Apixaban reduced thromboembolism risk in cancer patients
Cancer patients treated with apixaban had a significantly lower rate of venous thromboembolism but a higher risk of major bleeds than did those...
Conference Coverage
DOAC pause yields favorable outcomes for AF patients
SAN DIEGO – Results from the PAUSE study could set the standard for timing of perioperative DOAC interruption.
Conference Coverage
Emapalumab safe, effective in pediatric primary hemophagocytic lymphohistiocytosis
SAN DIEGO – There is “certainly room for enlarging the indication” to first-line treatment of HLH once a sufficient number of previously untreated...
News
New VTE guidelines include over 150 recommendations
The American Society of Hematology (ASH) has released a new set of guidelines for the prevention, diagnosis, and management of venous...
Video
ARISTOPHANES: Apixaban edges other DOACS for octogenarians
CHICAGO – Insurance claims data from more than 50,000 U.S. octogenarians on a DOAC showed apixaban worked best and caused the fewest major bleeds...
Conference Coverage
Your guide to ASH 2018: Abstracts to watch
News
EC approves product for hemophilia A
The European Commission (EC) has approved damoctocog alfa pegol (Jivi®), a recombinant human factor VIII therapy. Damoctocog alfa pegol (formerly...
Guidelines
ASH releases new VTE guidelines
A panel of the American Society of Hematology released more than 150 recommendations for dealing with venous thromboembolism.
News
Canada expands approval for antihemophilic factor
Health Canada has extended the approved indication for Adynovate, a recombinant pegylated factor VIII (FVIII) product, in patients with hemophilia...
Conference Coverage
Tofacitinib and TNF inhibitors show similar VTE rates
A review of more than 50,000 U.S. rheumatoid arthritis patients shows similar venous thromboembolism rates with tofacitinib and TNF inhibition.
From the Journals
All patients with VTE have a high risk of recurrence
Researchers suggest rethinking categorization of patients with incident venous thromboembolism.